Males of the self-limiting strain of the Aedes aegypti mosquito are modified so their offspring die before being able to reproduce, says Intrexon, a U.S. synthetic biology company.
The FDA findings agree with the draft environmental assessment submitted by Oxitec, the UK unit of Intrexon that developed the mosquito.
The company’s stock was up about 3 percent at $35.93 in early trading on Friday.